Genfit is a biopharmaceutical company engaged in the discovery and development of drugs and biomarkers in therapeutic areas of high unmet need due to the lack of effective treatments or diagnostic tools and/or due to the increasing number of patients worldwide. Co. concentrates its research and development efforts to participate in the commercialization of treatment solutions and diagnostic tools to fight certain metabolic, inflammatory, autoimmune or fibrotic diseases affecting especially the liver (such as non-alcoholic steatohepatitis or "NASH").
  • TickerALGFT
  • ISINFR0004163111
  • ExchangeEuronext Paris
  • SectorPharmaceuticals & Biotechnology
  • CountryFrance

Analysts

Team Pharma

ODDO : « Biotech 2019 : la visibilité financière avant tout »

Nous actualisons notre hiérarchie sectorielle biotech en ce début d’année 2019 (15 valeurs). Nous préconisons les sociétés avec un newsflow majeur, focalisées sur un domaine thérapeutique porteur et sans risque cash. Ainsi, nous recommandons à l’Achat Cellectis (OC 26 € - Initiation de couverture), Genfit (OC 63 € vs 59 €), Innate Pharma (OC 11.6 € vs 10.9 € - Top pick) et Orphazyme (OC 96 DKK vs 107 DKK), alors que nous devenons plus prudents sur Genkyotex (Alléger vs Achat - OC...

Team Pharma

ODDO : Biotech stocks in 2019: focus on financial visibility

We have reviewed our biotech sector hierarchy at the start of 2019 (15 stocks). We favour companies with major newsflow, a focus on a specific high-growth therapeutic area and a solid cash position. On this basis, we are at Buy on Cellectis (TP € 26 - initiation of coverage), Genfit (TP € 63 vs € 59), Innate Pharma (TP € 11.6 vs € 10.9 - top pick) and Orphazyme (TP DKK 96 vs DKK 107) and have become more cautious on Genkyotex (Reduce vs Buy, TP € 1.0 vs € 3.4) and Neutral on DBV ...

Oussema Denguir ...
  • Pierre Corby

Genfit : Good progress in NASH diagnostics

>Partnership with Labcorp for a NASH diagnostic test - Genfit announced yesterday morning that it had signed a non-exclusive licensing agreement with Labcorp (Covance) concerning a non-invasive NASH diagnostic test. This announcement is in line with Genfit’s declared goal of finding a partner for the development and future marketing of a non-invasive NASH test in 2020/2021. Note that at present, diagnosing NASH involves a liver biopsy (the current standard), which has...

Jean-Jacques Le Fur

GENFIT: Very strong phase II results in PBC | BUY | EUR65

GENFIT - BUY | EUR65(+222%) Very strong phase II results in PBC The best reduction in ALP Good safety for elafibranor, an advantage over Ocaliva PBC not the biggest potential but another winning card

Antoine Boivin-Champeaux ...
  • Charles Lepetitpas
  • Florent Laroche-Joubert
  • Nicolas David
  • Oussema Denguir
  • Pierre Corby
  • Stephane Houri
  • Yan Derocles

ODDO BHF Small & MIDCAP MORNING NEWS - 12/06/2018

...

Team Pharma

ODDO : « Biotech 2019 : la visibilité financière avant tout »

Nous actualisons notre hiérarchie sectorielle biotech en ce début d’année 2019 (15 valeurs). Nous préconisons les sociétés avec un newsflow majeur, focalisées sur un domaine thérapeutique porteur et sans risque cash. Ainsi, nous recommandons à l’Achat Cellectis (OC 26 € - Initiation de couverture), Genfit (OC 63 € vs 59 €), Innate Pharma (OC 11.6 € vs 10.9 € - Top pick) et Orphazyme (OC 96 DKK vs 107 DKK), alors que nous devenons plus prudents sur Genkyotex (Alléger vs Achat - OC...

Team Pharma

ODDO : Biotech stocks in 2019: focus on financial visibility

We have reviewed our biotech sector hierarchy at the start of 2019 (15 stocks). We favour companies with major newsflow, a focus on a specific high-growth therapeutic area and a solid cash position. On this basis, we are at Buy on Cellectis (TP € 26 - initiation of coverage), Genfit (TP € 63 vs € 59), Innate Pharma (TP € 11.6 vs € 10.9 - top pick) and Orphazyme (TP DKK 96 vs DKK 107) and have become more cautious on Genkyotex (Reduce vs Buy, TP € 1.0 vs € 3.4) and Neutral on DBV ...

Oussema Denguir ...
  • Pierre Corby

Genfit : Good progress in NASH diagnostics

>Partnership with Labcorp for a NASH diagnostic test - Genfit announced yesterday morning that it had signed a non-exclusive licensing agreement with Labcorp (Covance) concerning a non-invasive NASH diagnostic test. This announcement is in line with Genfit’s declared goal of finding a partner for the development and future marketing of a non-invasive NASH test in 2020/2021. Note that at present, diagnosing NASH involves a liver biopsy (the current standard), which has...

Jean-Jacques Le Fur

GENFIT: Very strong phase II results in PBC | BUY | EUR65

GENFIT - BUY | EUR65(+222%) Very strong phase II results in PBC The best reduction in ALP Good safety for elafibranor, an advantage over Ocaliva PBC not the biggest potential but another winning card

Oussema Denguir ...
  • Pierre Corby

Genfit : Elafibranor, a potentiel best-in-class in PBC (primary biliary cholangitis)?

>Elafibranor: positive phase II results in PBC, towards phase III - We were waiting for the results of phase II of Elafibranor in Primary Biliary Cholangitis (PBC) in December. Here they are and the results are positive. PBC is a rare chronic liver disease characterised by damaged intrahepatic bile ducts that can lead to cirrhosis. The primary endpoint of the study was reached and was statistically significant: serum alkaline phosphatase (ALP) concentration after 12 w...

A director bought 83,333 shares at 22.200EUR and

A director at Genfit bought 83,333 shares at 22.200EUR and the significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of board...

Antoine Boivin-Champeaux ...
  • Charles Lepetitpas
  • Florent Laroche-Joubert
  • Nicolas David
  • Oussema Denguir
  • Pierre Corby
  • Stephane Houri
  • Yan Derocles

ODDO BHF Small & MIDCAP MORNING NEWS - 12/06/2018

...

GENFIT sees a downgrade to Slightly Negative on account of less fundamental stars

The independent financial analyst theScreener just lowered the general evaluation of GENFIT (FR), active in the Biotechnology industry. As regards its fundamental valuation, the title now shows 0 out of 4 stars while market behaviour can be considered moderately risky. theScreener believes that the title remains under pressure due to the loss of a star(s) and downgrades its general evaluation to Slightly Negative. As of the analysis date September 25, 2018, the closing price was EUR 21.60 and its target price was estimated at EUR 19.97.

Ford Equity International Rating and Forecast Report

Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind each recommendation and reflect the fundamental and price data as of the last trading day of the week...

Jehanne Leroy

Proxy Report - 15/06/2018

Alors même que la société recueillait l’an dernier des taux d’approbation assez faibles sur ses autorisations financières, principalement en raison de leur maintien en période d’offre publique, elle réitère cette année, sourde à la contestation de ses actionnaires. Ainsi, comme l’année dernière, Proxinvest ne soutiendra pas ces autorisations, non seulement en raison du maintien en période d’offre publique, mais également en raison des montants demandés dans le cas des autorisations sans DPS. De la même façon, alors que la plupart des sociétés du SBF120 proposent des rémunérations sous forme d...

Matthieu DRIOL

Short term view - GENFIT : Rising consolidation.

The background trend is clearly bearish. The negative MACD confirms the trend. The rise is a consolidation that will soon bump against the level at €21.90. The next target is at €17.80, then €16.50. Passing €28.28 would question the continuation of the fall.

Matthieu DRIOL

Analyse court terme - GENFIT : La reprise est une consolidation.

La tendance de fond est clairement orientée à la baisse. Le MACD est négatif, il confirme cette tendance. La reprise est une consolidation qui va buter sur 21,90 € prochainement. Le prochain objectif est à 17,80 €, puis 16,50 €. Le franchissement de 28,28 € remettrait en cause la suite de la baisse.

Matthieu DRIOL

Short term view - GENFIT : Falling prices.

The background trend is clearly bearish. Prices are falling again, but the movement has become hesitant. The next support is at €17.80. The background trend would be questioned should prices rise above €28.28.

Matthieu DRIOL

Analyse court terme - GENFIT : Les prix baissent.

La tendance de fond est clairement orientée à la baisse. Les prix baissent à nouveau, mais le mouvement est devenu hésitant. Le prochain support est à 17,80 €. La tendance de fond serait remise en cause en cas de franchissement de 28,28 €.

Matthieu DRIOL

Medium term view - GENFIT : The movement goes on.

The background trend is clearly bearish. The movement goes on. The next target is at €16.30, then €6.74. Passing €35.59 would question the continuation of the fall.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch